GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
3

3SBio 1530.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

15.16

-0.13%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About 3SBio

Its shares trade on HKEX under the ticker 1530.HK. It has been listed since 11 June 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥20.61bn and net income of CN¥9.88bn. At that date it held total assets of CN¥42.23bn and shareholders' equity of CN¥31.70bn.

3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products. The company is headquartered in Shenyang, Liaoning. The company went IPO on 2015-06-11. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The firm distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
11 Jun 2015
Employees
5,404
Website
3sbio.com ↗

Leadership

Pay as last reported

  • Mr. Jing LouExecutive Chairman of the Board, President, Chief Executive Officer, since 2006CN¥8.1m
  • Mr. Xiang HeChief Financial Officer
  • Ms. Dongmei SuSenior Vice President, General Manager - Shenyang Sunshine, Executive DirectorCN¥1.5m
  • Mr. Zheng JinGeneral Manager - Shenyang Sunshine
  • Mr. Yong XuGeneral Manager, Director of Sciprogen
  • Mr. An YuGeneral Manager, Executive Director of Sunshine Mandi
  • Ms. Siu Kuen LaiCompany Secretary, since 2022
  • Ms. Yanli LiuVice General Manager and Secretary to the Board of Sunshine Guojian, since 2019
  • Ms. Jiaoe ZhangNon-Executive DirectorCN¥406,000
  • Mr. Joo Yeow NgNon-Executive Independent DirectorCN¥274,000
  • Mr. Tianruo PuIndependent Non-Executive DirectorCN¥274,000
  • Ms. Hoi Ti Heidi YangNon-Executive Independent DirectorCN¥274,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
89
Environment
96
Social
99
Governance
71
Direct emissions (scope 1)
13,304.07 t
Energy emissions (scope 2)
53,966.8 t
Value chain emissions (scope 3)
20,793,853 t
Women in the workforce
53.18271%
Carbon reduction policy
No
Human rights policy
Yes

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.